Mölleken, C., Ahrens, M., Schlosser, A., Dietz, J., Eisenacher, M., Meyer, H. E., . . . Bracht, T. (2019). Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. Clin Mol Hepatol.
Chicago ZitierstilMölleken, Christian, et al. "Direct-acting Antivirals-based Therapy Decreases Hepatic Fibrosis Serum Biomarker Microfibrillar-associated Protein 4 in Hepatitis C Patients." Clin Mol Hepatol 2019.
MLA ZitierstilMölleken, Christian, et al. "Direct-acting Antivirals-based Therapy Decreases Hepatic Fibrosis Serum Biomarker Microfibrillar-associated Protein 4 in Hepatitis C Patients." Clin Mol Hepatol 2019.
Achtung: Diese Zitate sind unter Umständen nicht zu 100% korrekt.